Skip to main content
Figure 6 | Breast Cancer Research

Figure 6

From: Inducible and coupled expression of the polyomavirus middle T antigen and Cre recombinase in transgenic mice: an in vivo model for synthetic viability in mammary tumour progression

Figure 6

Recurrent masses from de-induced rtTA/MIC mice have variable histopathologies and some exhibit re-expression of PyV mT. (A) H&E-stained recurrent mammary tumours arising in rtTA/MIC mice post-doxycycline withdrawal. The mouse ID number (followed by the tumour location in the case of multiple recurrences, for example, “R1”) and histopathology of the tumour are indicated for each image. A pre-regression rtTA/MIC doxycycline-dependent mammary tumour exhibiting typical end-stage adenocarcinoma is shown for comparison. (Scale bar: 100 μm). (B) Immunoblot analysis of protein lysates from rtTA/MIC mammary tumours prior to and following doxycycline withdrawal using antibodies directed to E-cadherin (epithelial content control), PyV mT, Cre recombinase and Hsp90 (loading control); the arrowhead indicates the specific band for PyV mT protein. Resected mammary tumours were used for pre- and mid-regression time-points (pre- and mid-, respectively), while recurrent masses were harvested from mice sacrificed at clinical endpoint. The mouse ID numbers of the recurrent tumour lysates are indicated and correspond to the images labeled in (A). The incidence of adenocarcinoma in the corresponding histological section for each sample is indicated by a “+” symbol.

Back to article page